Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes

被引:66
作者
Mason, JO
Somaiya, MD
Singh, RJ
机构
[1] Univ Alabama, Retina Consultants Alabama PC, Birmingham, AL 35233 USA
[2] Callahan Eye Fdn Hosp, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2004年 / 24卷 / 06期
关键词
intravitreal concentration; pharmacokinetics; triamcinolone acetonide;
D O I
10.1097/00006982-200412000-00009
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the intravitreal concentration and clearance of triamcinolone acetonide at various intervals after intravitreal injection into nonvitrectomized eyes. Methods: Six participants were administered 4 mg (0.1 cc) of triamcinolone acetonide ophthalmic suspension. All six eyes underwent therapeutic pars plana vitrectomy with membranectomy at various post injection intervals ranging from 1.25 to 5 months from the intravitreal injection. Undiluted specimens of vitreous overlying the macula and of aqueous humor were submitted for analysis. Vitreous and aqueous humor concentrations of triamcinolone were measured by high performance liquid chromatography. Results: Four eyes demonstrated detectable intravitreal concentrations of triamcinolone acetonide between 1.25 and 2.75 months after a single injection. Two eyes had an undetectable level of triamcinolone in both the vitreous and aqueous at 3 and 5 months post single injection. Conclusions: The intravitreal concentration of triamcinolone acetonide is detectable up to 2.75 months post a single 4 mg injection in nonvitrectomized eyes. A reinjection interval of 3 months may be needed to achieve sustained measurable levels of triamcinolone in nonvitrectomized patients.
引用
收藏
页码:900 / 904
页数:5
相关论文
共 24 条
[1]   Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study [J].
Antcliff, RJ ;
Spalton, DJ ;
Stanford, MR ;
Graham, EM ;
Ffytche, TJ ;
Marshall, J .
OPHTHALMOLOGY, 2001, 108 (04) :765-772
[2]   THE EFFECTS OF INTRAVITREAL TRIAMCINOLONE ACETONIDE ON EXPERIMENTAL PRERETINAL NEOVASCULARIZATION [J].
ANTOSZYK, AN ;
GOTTLIEB, JL ;
MACHEMER, R ;
HATCHELL, DL .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1993, 231 (01) :34-40
[3]   Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection [J].
Beer, PM ;
Bakri, SJ ;
Singh, RJ ;
Liu, WG ;
Peters, GB ;
Miller, M .
OPHTHALMOLOGY, 2003, 110 (04) :681-686
[4]   IMPROVEMENT IN EFFICACY OF CORTICOSTEROID-THERAPY IN AN ANIMAL-MODEL OF PROLIFERATIVE VITREORETINOPATHY BY PRETREATMENT [J].
CHANDLER, DB ;
HIDA, T ;
SHETA, S ;
PROIA, AD ;
MACHEMER, R .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1987, 225 (04) :259-265
[5]   INTRAVITREAL CORTICOSTEROIDS IN THE TREATMENT OF EXOGENOUS FUNGAL ENDOPHTHALMITIS [J].
COATS, ML ;
PEYMAN, GA .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1992, 12 (01) :46-51
[6]  
Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
[7]   INTRAVITREAL INJECTION OF DEXAMETHASONE - TREATMENT OF EXPERIMENTALLY INDUCED ENDOPHTHALMITIS [J].
GRAHAM, RO ;
PEYMAN, GA .
ARCHIVES OF OPHTHALMOLOGY, 1974, 92 (02) :149-154
[8]   EXPERIMENTAL AND CLINICAL OBSERVATIONS OF THE INTRAOCULAR TOXICITY OF COMMERCIAL CORTICOSTEROID PREPARATIONS [J].
HIDA, T ;
CHANDLER, D ;
ARENA, JE ;
MACHEMER, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (02) :190-195
[9]  
Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
[10]  
Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57